Alan Dunton

Dr. Alan W.
Dunton, MD, is an Independent Non-Executive Director at Recce Pharmaceuticals Ltd., an Independent Director at CorMedix, Inc., an Independent Director at Palatin Technologies, Inc. and an Independent Director at Oragenics, Inc. He is on the Board of Directors at Recce Pharmaceuticals Ltd., CorMedix, Inc., Cytogel Pharma LLC, Palatin Technologies, Inc., Oragenics, Inc. and ActivBiotics, Inc. Dr. Dunton was previously employed as an Independent Non-Executive Director by Regeneus Ltd., a SVP-Regulatory Affairs, Research & Development by Purdue Pharma LP, a Non-Executive Director by Bionomics Ltd., a Chief Medical Officer by Derma Sciences, Inc., a Non-Executive Chairman by EpiCept Corp., a Chief Medical Officer by Marina Biotech, Inc., a Managing Director by Panacos Pharmaceuticals, Inc., an Independent Director by Targacept, Inc., a Principal Owner by Danerius LLC, a President & Chief Executive Officer by Metaphore Pharmaceuticals, Inc., a President, Chief Operating Officer & Director by Emisphere Technologies, Inc., a President & Managing Director by The Janssen Research Foundation, a Senior Executive by Johnson & Johnson, a Vice President-Clinical Research & Development by Syntex Corp., a Vice President-Clinical Research & Development by Ciba-Geigy Corp., a Vice President-Clinical Research & Development by Hoffmann-La Roche, Inc., a Chairman by Janssen-Cilag International NV, a Member-Group Operating Committee by Johnson & Johnson Pharmaceutical Group, a Senior Vice President-Research & Development by Purdue Pharmaceuticals LP, and a VP-Global Clinical Research & Development by R.W.
Johnson Pharmaceutical Research Institute.
He also served on the board at Sancilio Pharmaceuticals Co., Inc., Sancilio & Co., Inc., VWR International LLC, Adams Respiratory Therapeutics, Inc., MediciNova, Inc. and Vicuron Pharmaceuticals Inc.